Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-301 in Relapsed or Refractory AML, MDS, or MDS/MPN
NCT04639024Phase 2Terminated
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camidanlumab tesirine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Myeloproliferative Neoplasm (MPN). Primary endpoints: Complete Remission (CR) or Complete Remission With Incomplete Count Recovery (CRi) at 11 months and Dose Limiting Toxicities at 7 months. Started Dec 2021; status: terminated.
02
Drugs
camidanlumab tesirine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04639024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639024.